Moreover, the activation of the PI3K/AKT/GSK‐3β pathway by the PI3K agonist 740Y‐P facilitated oncogenic behaviors in HCC cells; however, these effects were significantly mitigated by salvigenin therapy. Here, PIK3CB is linked to hepatocellular carcinoma.